Meanwhile, there was bad blood between cell therapy players and their investors.
Roche and Bristol Myers Squibb look to have the industry’s next most advanced assets against GPRC5D.
Investors got jittery on Friday, and for good reason: like all allogeneic cell therapy players Adicet is seeing patients relapse.
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Data in the desmoid tumour niche look strong, but Ayala might provide a cheaper way for investors to play in gamma secretase inhibition.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.